Harkensee Christian, Vasdev Nikhil, Gennery Andrew R, Willetts Ian E, Taylor Clive
Supra-regional Children's Bone Marrow Transplant Unit (CBMTU), Newcastle General Hospital, Newcastle upon Tyne, UK.
Br J Haematol. 2008 Sep;142(5):717-31. doi: 10.1111/j.1365-2141.2008.07254.x. Epub 2008 Jun 6.
Haemorrhagic cystitis (HC) is a common and, in its severe form, potentially life-threatening complication of Haematopoietic stem cell transplantation (HSCT) in children. Recent data indicate an important role of BK virus reactivation during the time of maximal post-transplant immune suppression in the pathogenesis of late-onset HC. Treatment of HC is mainly symptomatic and often frustrating. To give clinicians guidance on prevention and treatment options and their backing by scientific evidence, we have systematically assessed the available literature and devised evidence-based guidelines. Our comprehensive review demonstrates that evidence for the most commonly used interventions (such as cidofovir, oestrogen, hyperbaric oxygen, bladder instillation with formalin, alum salts or prostaglandin) is very limited. Some of these interventions also carry significant risks. Higher level evidence exists only for 2-mercaptoethane sodium (MESNA) and hyperhydration as a preventative intervention, and for systemic recombinant Factor VII as a treatment to stop acute haemorrhage. Further high-quality studies are required to establish effective and safe prevention and treatment options for HC.
出血性膀胱炎(HC)是儿童造血干细胞移植(HSCT)常见的并发症,严重时可能危及生命。近期数据表明,在移植后免疫抑制最强的时期,BK病毒再激活在迟发性HC发病机制中起重要作用。HC的治疗主要是对症治疗,且往往令人沮丧。为了为临床医生提供预防和治疗方案及其科学依据方面的指导,我们系统评估了现有文献并制定了循证指南。我们的全面综述表明,最常用干预措施(如西多福韦、雌激素、高压氧、膀胱灌注福尔马林、铝盐或前列腺素)的证据非常有限。其中一些干预措施也有重大风险。仅在作为预防性干预措施的2-巯基乙烷磺酸钠(美司钠)和水化疗法,以及作为治疗急性出血的全身性重组凝血因子VII方面存在更高级别的证据。需要进一步开展高质量研究以确定有效且安全的HC预防和治疗方案。